Palatin Technologies Inc - Company & Market Research Reports

Palatin Technologies is a biopharmaceutical company that develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s leading product is Bremelanotide, which is used to treat hypoactive sexual desire disorder (HSDD). It has completed pivotal Phase 3 clinical trials. Palatin also has development programs or drug candidates for inflammatory disease indications, heart failure and fibrosis. It was founded in 1986 and is based in Cranbury, New Jersey.

From
From
Ulcerative Colitis - Pipeline Review, H2 2018 - Product Thumbnail Image

Ulcerative Colitis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 542 Pages
From
Ulcerative Colitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Ulcerative Colitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 482 Pages
From
From
Uveitis - Pipeline Review, H2 2018 - Product Thumbnail Image

Uveitis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 207 Pages
From
Uveitis - Pipeline Review, H1 2018 - Product Thumbnail Image

Uveitis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 195 Pages
From
From
From
Obesity - Pipeline Review, H1 2018 - Product Thumbnail Image

Obesity - Pipeline Review, H1 2018

  • Drug Pipelines
  • 526 Pages
From
Obesity - Pipeline Review, H2 2017 - Product Thumbnail Image

Obesity - Pipeline Review, H2 2017

  • Drug Pipelines
  • 518 Pages
From
From
From
From
From
Type 2 Diabetes - Pipeline Review, H1 2018 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1109 Pages
From
From
From
From
From
Loading Indicator
adroll